HC Wainwright Reaffirms “Buy” Rating for Vascular Biogenics Ltd. (VBLT)

Vascular Biogenics Ltd. (NASDAQ:VBLT)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Tuesday, November 7th. They presently have a $11.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 57.14% from the company’s current price.

Several other equities analysts have also commented on the company. Chardan Capital increased their price objective on Vascular Biogenics from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, November 6th. Zacks Investment Research upgraded Vascular Biogenics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 19th. Finally, ValuEngine upgraded Vascular Biogenics from a “sell” rating to a “hold” rating in a research report on Wednesday, September 20th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $16.00.

Vascular Biogenics (NASDAQ VBLT) opened at $7.00 on Tuesday. Vascular Biogenics has a one year low of $3.90 and a one year high of $9.05.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/11/24/vascular-biogenics-ltd-vblt-receives-buy-rating-from-hc-wainwright.html.

An institutional investor recently bought a new position in Vascular Biogenics stock. KCG Holdings Inc. bought a new stake in Vascular Biogenics Ltd. (NASDAQ:VBLT) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 45,106 shares of the biopharmaceutical company’s stock, valued at approximately $248,000. KCG Holdings Inc. owned 0.17% of Vascular Biogenics as of its most recent SEC filing. 7.26% of the stock is owned by institutional investors and hedge funds.

Vascular Biogenics Company Profile

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Receive News & Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply